Tenofovir Disoproxil Emtricitabine Mylan 300/200 Tablets
Reason for Recall / Hazard
Potential for broken and/or split tablets. In the event a broken/split tablet is consumed, this may result in an ineffective dose if the tablet is not taken in its entirety.
Product Description & Identification
Reason / Defects: Potential for broken and/or split tablets. In the event a broken/split tablet is consumed, this may result in an ineffective dose if the tablet is not taken in its entirety. Hazards: A broken or split tablet may lead to ineffective dosing, which may increase the risk of adverse health effects. What to do: Consumers that have been prescribed Tenofovir Disoproxil Emtricitabine Mylan 300/200 should consult their treating physician for advice. Consumers that have any unexpired product should return the product to their pharmacist for a refund. A TGA web statement can be found at https://www.tga.gov.au/alert/tenofovir-disoproxil-emtricitabine-mylan-300200 For further information, please contact Alphapharm on 1800 274 276.
Affected Products
Tenofovir Disoproxil Emtricitabine Mylan 300/200 tenofovir disoproxil maleate 300 mg and emtricitabine 200 mg film coated tablets All batches within expiry ARTG: 265834 Prescription Medicine for: The treatment of HIV-infected adults over the age of 18 years, in combination with other antiretroviral agents. In combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults at high risk.
Additional Source Details
| Field | Value |
|---|---|
| Guid › #text | 9abe8c65-241c-4516-8195-9d9c056d85ea |
| Guid › @ is Perma Link | false |
| Link | https://www.productsafety.gov.au/search-consumer-product-recalls/tenofovir-disoproxil-emtricitabine-mylan-300200-tablets |
| Pub Date | Thu, 14 Jan 2021 00:00:00 +0000 |
| Extracted image | https://www.productsafety.gov.au/system/files/styles/large/private/Tenofovir%20Disoproxil%20Emtricitabine%20Mylan%20Bottle.jpg?itok=CgI_2K4R |